OptiNose (OPTN)
(Delayed Data from NSDQ)
$1.17 USD
+0.06 (5.41%)
Updated May 28, 2024 04:00 PM ET
After-Market: $1.18 +0.01 (0.85%) 6:48 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Brokerage Reports
OptiNose, Inc. [OPTN]
Reports for Purchase
Showing records 1 - 3 ( 3 total )
Company: OptiNose, Inc.
Industry: Medical - Drugs
XHANCE Label Extension Defines First FDA Approval for CRSsNP Patients; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: OptiNose, Inc.
Industry: Medical - Drugs
Near-Term XHANCE PDUFA for First Approval in Chronic Sinusitis Without Nasal Polyps; Initiating With Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: OptiNose, Inc.
Industry: Medical - Drugs
|